CFRA cuts Bristol-Myers to hold; sees limited upside
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bristol-Myers Squibb Company (BMY)Bristol-Myers Squibb Company stock price live, this page displays NYSE BMY stock exchange data. View the BMY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Bristol-Myers Squibb Company real time stock price chart below.
What Is the Bristol-Myers Squibb Company Stock Price Today?
The Bristol-Myers Squibb Company stock price today is 55.88.
What Is the Stock Symbol for Bristol-Myers Squibb Company?
The stock symbol for Bristol-Myers Squibb Company is "BMY."
What Stock Exchange Does Bristol-Myers Squibb Company Trade On?
Bristol-Myers Squibb Company is listed and trades on the NYSE stock exchange.
Is Bristol-Myers Squibb Company a Good Stock to Buy?
Determining whether Bristol-Myers Squibb Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BMY quote. (ISIN: US1101221083)
What Is the Bristol-Myers Squibb Company Stock Price Today?
The Bristol-Myers Squibb Company stock price today is 55.88.
What Is the Stock Symbol for Bristol-Myers Squibb Company?
The stock symbol for Bristol-Myers Squibb Company is "BMY."
What Stock Exchange Does Bristol-Myers Squibb Company Trade On?
Bristol-Myers Squibb Company is listed and trades on the NYSE stock exchange.
Is Bristol-Myers Squibb Company a Good Stock to Buy?
Determining whether Bristol-Myers Squibb Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BMY quote. (ISIN: US1101221083)
55.88
+0.35(+0.63%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
55.39
56.00
52 wk Range
36.46
58.51
BMY Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
High dividend Yield
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
55.3956.00
52 wk Range
36.4658.51
Key Statistics
Edit
Fair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
Unlock(4.08%)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
Unlock(4.08%)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockBMY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Analysts Sentiment
Neutral
Price Target
60.43
Upside
+1.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
13 analysts have revised their earnings downwards for the upcoming period
Bristol-Myers Squibb Company Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Compare BMY to Peers and Sector
Metrics to compare | BMY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBMYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.4x | 11.7x | −0.7x | |
PEG Ratio | 0.09 | −0.03 | 0.00 | |
Price/Book | 7.0x | 1.9x | 2.6x | |
Price / LTM Sales | 2.5x | 4.1x | 3.2x | |
Upside (Analyst Target) | - | 62.1% | 44.1% | |
Fair Value Upside | Unlock | 14.2% | 8.2% | Unlock |
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -3.58
Dividend Yield
3.92%
Industry Median 2.40%
Annualised payout
2.1790
Paid quarterly
5-Years Growth
-
Growth Streak
FAQ
What Is the Bristol-Myers Squibb (BMY) Stock Price Today?
The Bristol-Myers Squibb stock price today is 55.88.
What Stock Exchange Does Bristol-Myers Squibb Trade On?
Bristol-Myers Squibb is listed and trades on the Frankfurt stock exchange.
What Is the Stock Symbol for Bristol-Myers Squibb?
The stock symbol for Bristol-Myers Squibb is "BMY."
Does Bristol-Myers Squibb Pay Dividends? What’s The Current Dividend Yield?
The Bristol-Myers Squibb Company dividend yield is 4.08%.
What Is the Bristol-Myers Squibb Market Cap?
As of today, Bristol-Myers Squibb market cap is 113.80B.
What is Bristol-Myers Squibb Earnings Per Share?
The Bristol-Myers Squibb EPS is -3.58.
From a Technical Analysis Perspective, Is BMY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.